These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8097540)
1. Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotamer-based dopamine receptor model". Seiler MP; Floersheim P; Markstein R; Widmer A J Med Chem; 1993 Apr; 36(8):977-84. PubMed ID: 8097540 [TBL] [Abstract][Full Text] [Related]
2. trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group. Seiler MP; Hagenbach A; Wüthrich HJ; Markstein R J Med Chem; 1991 Jan; 34(1):303-7. PubMed ID: 1671417 [TBL] [Abstract][Full Text] [Related]
3. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. Knoerzer TA; Nichols DE; Brewster WK; Watts VJ; Mottola D; Mailman RB J Med Chem; 1994 Jul; 37(15):2453-60. PubMed ID: 7914538 [TBL] [Abstract][Full Text] [Related]
4. trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. Brewster WK; Nichols DE; Riggs RM; Mottola DM; Lovenberg TW; Lewis MH; Mailman RB J Med Chem; 1990 Jun; 33(6):1756-64. PubMed ID: 1971308 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. Brewster WK; Nichols DE; Watts VJ; Riggs RM; Mottola D; Mailman RB J Med Chem; 1995 Jan; 38(2):318-27. PubMed ID: 7830274 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors. Knoerzer TA; Watts VJ; Nichols DE; Mailman RB J Med Chem; 1995 Aug; 38(16):3062-70. PubMed ID: 7636869 [TBL] [Abstract][Full Text] [Related]
7. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor model. Seiler MP; Markstein R; Walkinshaw MD; Boelsterli JJ Mol Pharmacol; 1989 May; 35(5):643-51. PubMed ID: 2566903 [TBL] [Abstract][Full Text] [Related]